CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC

The objective of this study is to assess safety and efficacy of CAB-AXL-ADC in NSCLC

Patients must not have clinically significant cardiac disease.
Patients must not have known non-controlled CNS metastasis.
Patients must not have had prior therapy with a conjugated or unconjugated auristatin derivative/vinca-binding site targeting payload.
Patients must not have a history of ≥ Grade 3 allergic reactions to mAb therapy as well as known or suspected allergy or intolerance to any agent given during this study.
Patients must not have had major surgery within 4 weeks before first BA3011
Patients must not have known human immunodeficiency virus (HIV) infection, active hepatitis B and/or hepatitis C.
Patients must not be women who are pregnant or breast feeding.

Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT04681131.

University of Pittsburgh Cancer Institute (UPCI)

Status: Active

Name Not Available

This is a multi-center, open-label, Phase 2 study designed to evaluate the safety,

tolerability, PK, immunogenicity, and antitumor activity of BA3011, a conditionally

active biologic (CAB) AXL-targeted antibody drug conjugate (CAB-AXL-ADC), alone and in

combination with PD-1 inhibitor in patients with metastatic non-small cell lung cancer

(NSCLC).

Trial PhasePhase II

Trial Typetreatment

Lead OrganizationBioAtla, Inc.

Description